{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:11:16Z","timestamp":1760854276340,"version":"3.41.2"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Invest Radiol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>In an effort to exploit the elevated need for phospholipids displayed by cancer cells relative to normal cells, we have developed tumor-targeted alkylphosphocholines (APCs) as broad-spectrum cancer imaging and therapy agents. Radioactive APC analogs have exhibited selective uptake and prolonged tumor retention in over 50 cancer types in preclinical models, as well as over 15 cancer types in over a dozen clinical trials. To push the structural limits of this platform, we recently added a chelating moiety capable of binding gadolinium and many other metals for cancer-targeted magnetic resonance imaging (MRI), positron emission tomography imaging, and targeted radionuclide therapy. The aim of this work was to synthesize, characterize, and validate the tumor selectivity of a new broad-spectrum, tumor-targeted, macrocyclic MRI chelate, Gd-NM600, in xenograft and orthotopic tumor models. A secondary aim was to identify and track the in vivo chemical speciation and spatial localization of this new chelate Gd-NM600 in order to assess its Gd deposition properties.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>T1 relaxivities of Gd-NM600 were characterized in water and plasma at 1.5 T and 3.0 T. Tumor uptake and subcellular localization studies were performed using transmission electron microscopy. We imaged 8 different preclinical models of human cancer over time and compared the T1-weighted imaging results to that of a commercial macrocyclic Gd chelate, Gd-DOTA. Finally, matrix-assisted laser desorption and ionization\u2013mass spectrometry imaging was used to characterize and map the tissue distribution of the chemical species of Gd-NM600.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Gd-NM600 exhibits high T1 relaxivity (approximately 16.4 s<jats:sup>\u22121<\/jats:sup>\/mM at 1.5 T), excellent tumor uptake (3.95 %ID\/g at 48 hours), prolonged tumor retention (7 days), and MRI conspicuity. Moreover, minimal tumor uptake saturability of Gd-NM600 was observed. Broad-spectrum tumor-specific uptake was demonstrated in 8 different human cancer models. Cancer cell uptake of Gd-NM600 via endosomal internalization and processing was revealed with transmission electron microscopy. Importantly, tissue mass spectrometry imaging successfully interrogated the spatial localization and chemical speciation of Gd compounds and also identified breakdown products of Gd species.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We have introduced a new macrocyclic cancer-targeted Gd chelate that achieves broad-spectrum tumor uptake and prolonged retention. Furthermore, we have demonstrated in vivo stability of Gd-NM600 by ultrahigh resolution MS tissue imaging. A tumor-targeted contrast agent coupled with the enhanced imaging resolution of MRI relative to positron emission tomography may transform oncologic imaging.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rli.0000000000000893","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T13:00:18Z","timestamp":1655989218000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs"],"prefix":"10.1097","volume":"57","author":[{"given":"Ray R.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Brunnquell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Grudzinski","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjon","family":"Audhya","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamey P.","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"bib1-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI: developments, current challenges and future perspectives","volume":"33","year":"2016","journal-title":"Adv Ther"},{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/wnan.1198","article-title":"Gadolinium-based contrast agents for magnetic resonance cancer imaging","volume":"5","year":"2013","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"bib4-20250802","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/RLI.0000000000000731","article-title":"Molecular MR contrast agents","volume":"56","year":"2021","journal-title":"Invest Radiol"},{"key":"bib5-20250802","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1039\/b510982p","article-title":"Strategies for increasing the sensitivity of gadolinium based MRI contrast agents","volume":"35","year":"2006","journal-title":"Chem Soc Rev"},{"key":"bib6-20250802","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jmri.21969","article-title":"Biodistribution of gadolinium-based contrast agents, including gadolinium deposition","volume":"30","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"bib7-20250802","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.biomaterials.2016.02.002","article-title":"A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging","volume":"85","year":"2016","journal-title":"Biomaterials"},{"key":"bib8-20250802","first-page":"1967","article-title":"Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis","volume":"26","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib9-20250802","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(17)30158-8","article-title":"Gadolinium deposition in the brain: summary of evidence and recommendations","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"bib10-20250802","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/jm050252g","article-title":"Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues","volume":"49","year":"2006","journal-title":"J Med Chem"},{"key":"bib11-20250802","first-page":"240ra75","article-title":"Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib12-20250802","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2967\/jnumed.118.224808","article-title":"Preclinical characterization of 86\/90Y-NM600 in a variety of murine and human cancer tumor models","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib13-20250802","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrclinonc.2016.212","article-title":"Beyond the margins: real-time detection of cancer using targeted fluorophores","volume":"14","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"bib14-20250802","first-page":"522","article-title":"Low-dose radiation potentiates the propagation of anti-tumor immunity against melanoma tumor in the brain after in situ vaccination at a tumor outside the brain","volume":"195","year":"2021","journal-title":"Radiat Res"},{"key":"bib15-20250802","first-page":"1","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin\u2019s lymphoma","volume":"2","year":"2019","journal-title":"Commun Biol"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.7150\/thno.54881","article-title":"Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy","volume":"11","year":"2021","journal-title":"Theranostics"},{"key":"bib17-20250802","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","year":"2021","journal-title":"Sci Transl Med"},{"key":"bib18-20250802","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1021\/acs.molpharmaceut.8b01301","article-title":"In silico docking of alkylphosphocholine analogs to human serum albumin predicts partitioning and pharmacokinetics","volume":"16","year":"2019","journal-title":"Mol Pharm"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/cns-2016-0017","article-title":"Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies","volume":"5","year":"2016","journal-title":"CNS Oncol"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF00685608","article-title":"Alkylphosphocholines: a new class of membrane-active anticancer agents","volume":"32","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"e111652","DOI":"10.1371\/journal.pone.0111652","article-title":"A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/07357907.2015.1081691","article-title":"A phase 1, multi-center, open-label, dose-escalation study of 131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies","volume":"33","year":"2015","journal-title":"Cancer Invest"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1227\/NEU.0000000000000622","article-title":"Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection","volume":"76","year":"2015","journal-title":"Neurosurgery"},{"key":"bib24-20250802","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1148\/radiol.13121038","article-title":"PET\/MR imaging: technical aspects and potential clinical applications","volume":"267","year":"2013","journal-title":"Radiology"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1001\/jama.290.24.3199","article-title":"Whole-body dual-modality PET\/CT and whole-body MRI for tumor staging in oncology","volume":"290","year":"2003","journal-title":"JAMA"},{"key":"bib26-20250802","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2967\/jnumed.110.074773","article-title":"Hybrid PET\/MRI of intracranial masses: initial experiences and comparison to PET\/CT","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib27-20250802","first-page":"185","article-title":"MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis","volume":"42","year":"2017","journal-title":"Neurosurg Rev"},{"key":"bib28-20250802","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3171\/2016.1.JNS152077","article-title":"Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration","volume":"126","year":"2017","journal-title":"J Neurosurg"},{"key":"bib29-20250802","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1596\/neo.12432","article-title":"Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition","volume":"14","year":"2012","journal-title":"Neoplasia"},{"key":"bib30-20250802","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-12-0339","article-title":"Differential expression of 2\u2032,3\u2032-cyclic-nucleotide 3\u2032-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib31-20250802","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/1078-0432.CCR-13-1255","article-title":"\u03b1B-crystallin: a novel regulator of breast cancer metastasis to the brain","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"key":"bib32-20250802","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/mrm.21120","article-title":"Actual flip-angle imaging in the pulsed steady state: a method for rapid three-dimensional mapping of the transmitted radiofrequency field","volume":"57","year":"2007","journal-title":"Magn Reson Med"},{"key":"bib33-20250802","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nmeth1094","article-title":"MALDI imaging mass spectrometry: molecular snapshots of biochemical systems","volume":"4","year":"2007","journal-title":"Nat Methods"},{"key":"bib34-20250802","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.mri.2016.09.003","article-title":"Gadolinium deposition: is it chelated or dissociated gadolinium? How can we tell?","volume":"34","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"bib35-20250802","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.rli.0000184756.66360.d3","article-title":"Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths","volume":"40","year":"2005","journal-title":"Invest Radiol"},{"key":"bib36-20250802","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib37-20250802","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood.V98.13.3860","article-title":"The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas\/CD95 into membrane rafts in human leukemic cells","volume":"98","year":"2001","journal-title":"Blood"},{"key":"bib38-20250802","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/RLI.0000000000000467","article-title":"Methodological aspects for preclinical evaluation of gadolinium presence in brain tissue: critical appraisal and suggestions for harmonization\u2014a joint initiative","volume":"53","year":"2018","journal-title":"Invest Radiol"},{"key":"bib39-20250802","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/RLI.0000000000000241","article-title":"Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib40-20250802","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/RLI.0000000000000623","article-title":"Long-term evaluation of gadolinium retention in rat brain after single injection of a clinically relevant dose of gadolinium-based contrast agents","volume":"55","year":"2020","journal-title":"Invest Radiol"},{"key":"bib41-20250802","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","article-title":"Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C","volume":"43","year":"2008","journal-title":"Invest Radiol"},{"key":"bib42-20250802","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/RLI.0000000000000132","article-title":"T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib43-20250802","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3174\/ajnr.A1185","article-title":"Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide","volume":"29","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib44-20250802","first-page":"655","article-title":"A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours","volume":"46","year":"2004","journal-title":"Neuroradiology"},{"key":"bib45-20250802","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1148\/radiol.2402051266","article-title":"Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents","volume":"240","year":"2006","journal-title":"Radiology"},{"key":"bib46-20250802","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/jmri.21695","article-title":"Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla","volume":"29","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"bib47-20250802","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3174\/ajnr.A4154","article-title":"Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)","volume":"36","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib48-20250802","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib49-20250802","first-page":"834","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","year":"2013","journal-title":"Radiology"},{"key":"bib50-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00401-020-02159-1","article-title":"Histological features of gadolinium deposition in the brain, a case report","volume":"140","year":"2020","journal-title":"Acta Neuropathol"},{"key":"bib51-20250802","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00401-018-1857-4","article-title":"Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study","volume":"136","year":"2018","journal-title":"Acta Neuropathol"}],"container-title":["Investigative Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000000893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:09:31Z","timestamp":1754161771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rli.0000000000000893","relation":{},"ISSN":["1536-0210","0020-9996"],"issn-type":[{"type":"electronic","value":"1536-0210"},{"type":"print","value":"0020-9996"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}